Register for our free email digests:
Latest From EMD Serono Inc.
Bill Newell discusses the progress of Sutro’s commercialization programs on ADCs as well as lessons on leading a small biotech in a crowded competitive field of big pharma players.
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA has cleared four novel biologics without a suffix despite finalizing nonproprietary naming guidance; the agency requests sponsors submit proposed suffixes at the time a BLA is submitted.
Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.
- Therapeutic Areas
- North America
- Company Type
- Tech. Transfer Entity
- Parent & Subsidiaries
- Senior Management
- Mary Brainerd, Pres. & CEO
- Contact Info
Phone: (952) 853-8888
8170 33rd Ave.
Bloomington, MN 55425
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.